Suchergebnisse - "Geng, Xinran"

PubPharm (11)

1

53BP1 regulates heterochromatin through liquid phase separation

enthalten in: Nature communications | 2022

von Zhang, L. | Geng, X. | Wang, F. | +16

ErratumIn: Nat Commun. 2022 Feb 23;13(1):1088. - PMID 35197479

2

Glutathione-responsive PLGA nanocomplex for dual delivery of doxorubicin and curcumin to overcome tumor multidrug resistance

enthalten in: Nanomedicine (London, England) | 2021

von Lai, X. | Geng, X. | Li, M. | +6

3

Magnetic tri-bead microrobot assisted near-infrared triggered combined photothermal and chemotherapy of cancer cells

enthalten in: Scientific reports | 2021

von Song, X. | Chen, Z. | Zhang, X. | +5

4

Cardiac glycosides inhibit cancer through Na/K-ATPase-dependent cell death induction

enthalten in: Biochemical pharmacology | 2020

von Geng, X. | Wang, F. | Tian, D. | +8

5

Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy

enthalten in: Cancer letters | 2020

von Tian, D. | Tang, J. | Geng, X. | +6

6

HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1

enthalten in: Cells | 2020

von Moses, N. | Zhang, M. | Wu, J. | +8

7

Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer

enthalten in: Thoracic cancer | 2019

von Ding, S. | Song, X. | Geng, X. | +6

8

Hydrophilic Porous Poly(l-Lactic Acid) Nanomembranes : Self-Assembly, and Anti-Biofouling and Anti-Thrombosis Effects

enthalten in: ChemPlusChem | 2019

von Deng, X. | Zhang, M. | Tan, L. | +7

9

Small-Sized Cationic miRi-PCNPs Selectively Target the Kidneys for High-Efficiency Antifibrosis Treatment

enthalten in: Advanced healthcare materials | 2018

von Geng, X. | Zhang, M. | Lai, X. | +6

10

Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy

enthalten in: Biochemical and biophysical research communications | 2018

von Geng, X. | Ren, Y. | Wang, F. | +4